Buserelin in a superovulatory regimen for Holstein cows. I. Pituitary and ovarian hormone response in an experimental herd

Pharmacologic manipulation of fertility

The professional application of agents to the manipulation of fertility of cows requires basic and applied knowledge of the physiologic mechanisms that are affected and of the pharmacologic agents that are used. In all areas of the pharmacologic manipulation of fertility, the achievement is less than the ideal, and further research is required to improve the efficiency of treatments. The induction of estrus in acyclic animals can involve a reduction in the depth of anestrus, pretreatment with progestagen to ensure estrous behavior and the formation of a normal corpus luteum, and then treatment with exogenous gonadotropin. Responsiveness to treatment can be variable and reflects the depth of anestrus of the animals. Improved treatment regimens require a knowledge of the basic mechanisms involved with the depth of anestrus, a means of assessing the depth of anestrus, and an understanding of the hormonal requirements of ovarian follicles for development and maturation in animals at different depths of anestrus. The optimal precision in the synchronization of estrus (and ovulation) in cyclic animals requires the synchronization of both follicular waves and the end of progestational phase. The end of progestational phase can be synchronized effectively using prostaglandin F2a (or analogs), or by treatment with progestagens with or without luteolytic agents. Procedures to synchronize follicular waves need to be established. The induction of superovulation can be achieved readily using gonadotropins prior to estrus synchronization using prostaglandin F2a. The responses to standard treatments in terms of ovulation rates and yield of transferable embryos are highly variable. The development of procedures to reduce this variability requires an understanding of the intra-ovarian mechanisms involved in recruitment of follicles for a wave of follicular growth, in the selection of dominant follicles for further development, and in the mechanisms controlling follicular atresia. Cystic ovarian disease can be treated effectively using HCG or GnRH (follicular cysts) or prostaglandin F2a (luteal cysts). The basic mechanisms resulting in failure of estrogen positive feedback on LH secretion (that results in cystic follicles) remain to be determined. Small but significant increases in pregnancy rates can be achieved treating cows with prostaglandin during the post-partum period, with prostaglandin to induce estrus for insemination, with GnRH or HCG at estrus, and with GnRH or progestagen treatment during diestrus. Beneficial effects of treatment have been shown in some trials but not in others.(ABSTRACT TRUNCATED AT 400 WORDS)

Pattern of sex steroids secretion and their relationship with embryo yield in Jersey cows superovulated with PMSG

The levels of progesterone and estrogen secretion were studied in relationship to the superovulatory response in Jersey cows. Progesterone and estrogen concentrations were measured in superovulated Jersey cows with the objective of correlating the patterns of steroid secretion with embryo yield and quality. Pregnant mare serum gonadotropin (PMSG) was used in combination with prostaglandin F(2) alpha analogue to induce superovulation in 18 multiparous, cyclic cows. Serum progesterone and estradiol levels from cows which exhibited estrus within 24 to 48 h after prostaglandin administration (n=13) were used to estimate the superovulatory response. Sex steroid concentrations at the day of estrus (Day 0) was a strong indicator of embryo yield. Progesterone was negatively (r=-0.56) and estrogen positively (r=0.80) correlated to the number of embryos collected. Dramatic increase in progesterone from Day 0 to Day 7 was a significant indicator of embryo yield. A higher rise of estrogen in the follicular phase was an indicator of a larger number of growing follicles and, consequently, better superovulatory response. Nonresponding animals did not show any significant change in the hormonal profile from the day of PMSG treatment to the day of embryo collection. The estimation of progesterone and estradiol concentrations, simultaneously, gave a more objective prediction of embryo yield.

Buserelin in a superovulatory regimen for Holstein cows: II. Yield and quality of embryos in commercial herds

The gonadotropin releasing hormone analog, Buserelin, was tested in a superovulatory regimen in cows by administering 8 mug of it at the following times: Group I (12 cows), 48 h after the first prostaglandin F(2) alpha (PGF) injection: Group II (11 cows), 54 h after PGF: Group III (10 cows), 24 h after standing estrus was first observed; and Group IV (12 cows), served as superovulated controls. The cows were lactating Holsteins between 45 and 143 d post partum, with at least one estrus prior to superovulation. The number of embryos collected from Groups I, II, III and IV 7 d after estrus averaged 4.5, 8.1, 6.4 and 5.6, respectively (P>0.05). The fertilization rate in the three groups receiving Buserelin was 83 versus 76% for controls (P<0.10). Blood and milk samples taken just before starting follicle stimulating hormone treatment at the expected estrus and at the time of embryo recovery were tested for progesterone concentration, and results from a rapid ELISA test were useful in identifying cows that a) were unsuitable for superovulation, b) should have been in estrus but were not observed standing and c) produced few, if any, embryos.